In December 2019, China reported cluster of cases of pneumonia of unknown origin in Wuhan, Hubei province, which was communicated to World Health Organization (WHO) China office on December 31, 2019. With worldwide rapid spread of disease, the International Health Regulations Emergency Committee of WHO declared the outbreak as a "public health emergency of international concern" on January 30, 2020.[@bib1] The disease is caused by a new strain of beta corona virus,[@bib2] which was initially called as 2019 novel Corona virus (2019-nCoV) and subsequently designated as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by International Committee on Taxonomy of Viruses.[@bib3] On February 11, 2020, WHO designated the disease as *CO*rona *VI*rus *D*isease*-*20*19* (COVID-19). The virus continues to have unprecedented spread across the globe with significant impacts on healthcare systems and global economy. The outbreak was declared as pandemic on March 11, 2020, by WHO ([Figure 1](#fig1){ref-type="fig"} ).Figure 1Timeline of events.Figure 1

As per Center for Systems Science and Engineering at Johns Hopkins University, SARS-CoV-2 has infected 7,435,727 people worldwide causing 418,203 deaths. India reported its first case on January 30, 2020 with total number cases 286,577 with 8102 deaths as of June 11, 2020, 11.00pm IST.[@bib4] There is no approved therapy for COVID-19 at present, and more than 500 clinical trials are ongoing. The US FDA has authorized the use of hydroxychloroquine (HCQ) on March 20, 2020, and remdesivir on May 1, 2020, on emergency basis for treating patients with COVID-19.[@bib5] Keeping up with the current pace of information, we review the clinical studies of different therapeutic options available to treat COVID-19 as on June 11, 2020.

Viral lifecycle and pathogenesis {#sec1}
================================

New coronaviruses appear to infect humans periodically because of their wide distribution, zoonotic reservoirs, genetic diversity with frameshift genetic recombination and increased human-animal interface activities. SARS-CoV-2 belongs to *Betacoronavirus* genus which includes Bat SARS-like coronavirus, SARS-CoV, and Middle East Respiratory Syndrome (MERS)-CoV. Genome-wise analysis reveals about 96% genetic similarity of SARS-CoV-2 with Bat SARS-like coronavirus, 80% with SARS-CoV, and 50% with MERS-CoV. Bats are the wild reservoirs of Betacoronaviruses. SARS-CoV and SARS-CoV-2 attach to the host cell through angiotensin converting enzyme 2 (ACE-2) receptor while MERS-CoV through dipeptidyl peptidase 4. SARS-CoV-2 has lower case fatality rate (around 3%) and higher transmissibility (basic reproduction number R~0~ 2-2.5) as compared with SARS-CoV (9.5% and 1.7-1.9, respectively) and MERS-CoV (34.4% and 0.7, respectively).[@bib6]

SARS-CoV-2 is an enveloped, non-segmented, positive sense, single-stranded RNA virus. It has 4 structural proteins including spike (S) glycoprotein, envelope (E) glycoprotein, membrane (M) glycoprotein, nucleocapsid (N) protein, and several other non-structural proteins.

It is essential to understand the lifecycle of the virus and pathogenesis as it offers insights into potential therapeutic targets. The process of cellular entry of virus starts by attachment of S protein with angiotensin converting enzyme 2 (ACE-2) receptor on host cells (i.e. pneumocytes). Attachment occurs *via* binding domain of S protein to ACE-2 which is followed by fusion of viral membrane to host cell. After fusion, type 2 transmembrane serine protease (TMPRSS2) present on host cells clears ACE-2 and activates S protein. Activation of S protein causes conformational change allowing cellular entry of the virus. Thus, both ACE-2 and TMPRSS2 are important determinants of cellular entry and fusion ([Figure 2](#fig2){ref-type="fig"} ).[@bib7] Figure 2Lifecycle of the virus and potential therapeutic targets. ACE2, angiotensin converting enzyme 2; TMPRSS2, type 2 transmembrane serine protease.Figure 2

After cellular entry, genetic material of the virus (i.e. mRNA) gets injected into the cytoplasm for translation of 2 large replicative proteins pp1a and pp1b. Expression of these large polyproteins causes ribosomal frameshifting of upstream translation termination codon.[@bib8] Their continued synthesis and subsequent cleavage by proteinases yield membrane-bound replicase complex. This complex mediates both genomic replication and transcription of subgenomic mRNAs. These mRNAs translate structural and nonstructural proteins of the virus, which are assembled in endoplasmic reticulum and Golgi complex. These virions are subsequently released out of cell by exocytosis.[@bib9] This repeated cycle of cellular entry and exit infects adjacent pneumocytes and causes pneumonia (pulmonary phase) and subsequent systemic organ involvement. Few patients may have a phase of exuberant inflammatory response with cytokine storm. Drugs acting at different stages of viral lifecycle and disease phases have been summarized in [Table 1](#tbl1){ref-type="table"} .Table 1Treatment Options for SARS-CoV-2.Table 1ClassDrugsEntry inhibitorsCamostat mesylate (TMPRSS2)Fusion inhibitorsUmifenovir (Arbidol)Endocytosis inhibitorsChloroquine, Hydroxychloroquine, JAK-STAT inhibitors (Baricitinib, Ruxolitinib, Fedratinib)Protease inhibitorsLopinavir-ritonavir, DarunavirRNA-dependent RNA polymerase inhibitorsRemdisivir, Favipiravir, RibavirinImmunomodulatorsIL-6 inhibitors (Tocilizumab, Sarilumab), Chloroquine, HydroxychloroquineNeutralizing antibodiesConvalescent plasma exchange

Treatment {#sec2}
=========

There is no approved treatment for SARS-CoV-2 at present, and the current guidance is from previous treatment experiences of 2003 Severe Acute Respiratory Syndrome (SARS) and 2015 Middle East Respiratory Syndrome (MERS) outbreaks. Few drugs like chloroquine (CQ), remdesivir, and favipiravir have shown *in vitro* activity against SARS-CoV-2 and have been re-purposed for its treatment. Immunomodulatory therapies (i.e. interlukin-6 inhibitors) have been proposed for patients with hyperinflammatory response and convalescent plasma treatment for severe COVID-19 with multiorgan dysfunction. We briefly review and critically analyze the clinical experience with these treatment modalities, as of June 12, 2020.

Chloroquine and hydroxychloroquine {#sec3}
==================================

CQ and HCQ are structurally similar weak lipophilic bases with a hydroxyethyl group in HCQ in place of ethyl group of CQ. They are widely used in the treatment of malaria and other inflammatory disorders such as rheumatoid arthritis and systemic lupus erythematosus. *In vitro* studies using Vero cells have efficacy of CQ and HCQ against SARS-CoV-2. HCQ was seen to be more potent than CQ. Based on the pharmacologic properties, loading dose of 400 mg HCQ twice daily followed by 200 mg twice daily for 4 days was suggested.[@bib10]

Proposed antiviral and immunomodulatory actions of these drugs include lysosomotropic property, prevention of the conversion of toxic heme into non-toxic hemozoin (antimalarial activity), inhibition of glycosylation of host receptors, reduction of pro-inflammatory cytokines, reduced TNF-α production by activated macrophages, reduced expression of TNF-α receptors on monocytes, inhibition of toll-like receptors, inhibition of various processes in innate and adaptive immunity (immunoregulatory effect), decreased antigen presentation, and prevention of binding of anti-phospholipid antibodies (APLA) to Annexin5 which is a potent anticoagulant ([Figure 3](#fig3){ref-type="fig"} ). Both CQ and HCQ are weak bases and get concentrated in acidic organelles such as endosomes, golgi, and lysosomes. They increase intracellular pH, disrupt enzymatic processes, and cause cellular dysfunction. CQ and HCQ decreases intracellular iron by increasing endosomal pH and further impairing endosomal release of iron from transferrin. This change in iron levels also causes dysfunction of several intracellular enzymes involved in DNA replication. Thus, CQ and HCQ prevent cellular entry of enveloped viruses *via* endosomal routes along with impairment of late stages of viral replication.[@bib11] ^,^ [@bib12] Figure 3Antiviral and immunomodulatory effects of chloroquine and hydroxychloroquine. TLR, toll-like receptor.Figure 3

In February 2020, Gao *et al.* published first experience from China of more than 100 patients treated with chloroquine.[@bib13] They concluded that CQ is superior to control in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting virus negativity, and shortening the disease course. Based on this experience, it was recommended for treatment in the next set of guidelines issued by the National Health Commission of the People\'s Republic of China. However, no details regarding CQ dosage, characteristics of study population, or outcomes were provided to draw any meaningful conclusions ([Table 2](#tbl2){ref-type="table"} ).[@bib14] Chen *et al.* in a subsequent randomized control trial (RCT) from China had shown that there was no significant change in viral negativity and clinical outcomes in 30 patients of mild COVID-19 treated with HCQ.[@bib15] Another RCT of 62 patients from China by Chen *et al.* showed significant improvement in time to clinical recovery (fever and cough remission) and improved pneumonia (80.6% vs 54.8%) in patients treated with HCQ. Virologic outcomes were not assessed in this study.[@bib16] Table 2Clinical Studies of Hydroxychloroquine ± Azithromycin in Patients With COVID-19.Table 2AuthorsType of study (No. of patients)Treatment armsVirologic outcomesClinical outcomesICU stayAdverse eventsDeathCommentsGao J *et al.* Feb 2020, China[@bib13]Case series (n \> 100)CQPromotes virus negative conversionImproved lung imaging findings and shortens disease courseNRNRNRNo analyzable data reportedChen J *et al.* Mar 2020, China[@bib15]RCT (1:1) (n = 30)HCQ 200 mg 12hrly x 5 days vs ControlThroat swab on D7 (86.7% vs 93.3%), time to nucleic acid conversion (4 vs 2 d)No difference in time to fever remission, radiological progression (33.3% vs 46.7%)None4/15NoneNo significant change in viral load, mild disease, small numberChen Z *et al.* Apr 2020, China[@bib16]RCT (1:1) (n = 62)HCQ 200 mg 12hrly x 5 days vs ControlNRSignificant improvement in time to clinical recovery (fever and cough remission), improved pneumonia (80.6% vs 54.8%)4/31 in control arm2/31NoneMild disease with small number of patientsGautret P *et al.* Mar 2020, France[@bib17]Prospective, open-label non-RCT (n = 42)HCQ 200 mg 8hrly (n = 14) for 10 days ± AZT 500 mg on D1, 250 mg D2-5 (n = 6) vs ControlNasopharyngeal swab negative on D6 (100% in combination vs 57.1% in HCQ alone vs 12.5% in control)NRNoneNRNoneUnequal arms, 6 lost to follow-up, mild diseaseMolina JM *et al.* Mar 2020, France[@bib19]Prospective observational study (n = 11)HCQ 200 mg 8hrly for 10 days + AZT 500 mg on D1, 250 mg D2-5\
No control armNasopharyngeal swabs positive in 8/10 (80%) patients at D5-6Oxygen therapy 91%, ICU transfer 18%, Death 9%2/111/111/11Small number of patients with severe disease, clinical outcomes not well definedGautret P *et al.* Apr 2020, France[@bib18]Prospective observational study (n = 80)HCQ 200 mg 8hrly for 10 days + AZT 500 mg on D1, 250 mg D2-5\
No control armNasopharyngeal viral load (83% negative at D7, 93% at D8), Virus cultures negative in 97.5% D5Oxygen therapy 15%, ICU transfer 3.8%, Death 1.2%, Discharge 81.2%, mean length of stay of 5 days3/807/801/80First study with better case definition, 6 patients from previous study includedGeleris J *et al.* May 2020, USA[@bib20]Observational study (n = 1376)HCQ 600 mg 12hrly on D1, 400 mg 12hrly D2-5 (n = 811) vs ControlNRRespiratory failure developed in 346 patients (25.1%); 180 patients were intubated, and 166 died without intubationNR25.1%NRNo significant association with higher or lower risk of death or intubation; largest observational study with negative results[^1][^2]

Three studies were reported from France which studied role of HCQ and azithromycin in patients with mild COVID-19 ([Table 2](#tbl2){ref-type="table"}). Gautret *et al.* in a small cohort of 42 patients reported viral negativity in nasopharyngeal swab at Day 6 in all patients treated with HCQ and azithromycin combination versus 57.1% in patients receiving HCQ alone versus 12.5% in control arm. No clinical outcomes were reported.[@bib17] In an extension of this cohort, the same group subsequently reported experience of 80 patients with viral negativity in nasopharyngeal swab (83% negative at Day 7, 93% at Day 8) and in viral cultures (97.5% at Day 5). Majority of patients (81.2%) were discharged after median 5 days of hospitalization with 1 death.[@bib18] However, these virologic outcomes were not replicated by Molina *et al.* from France in which 80% nasopharyngeal swabs were positive at Day 5--6 in a small cohort of 11 patients.[@bib19]

In a largest observational study from United States, Geleris *et al.* recently published their experience of HCQ in a cohort of 1446 patients with mild to severe COVID-19 ([Table 2](#tbl2){ref-type="table"}). Seventy patients who were intubated, died, or discharged within 24 h of admission and were excluded from analysis. Primary endpoint was respiratory failure which was a composite of intubation or death. In patients who died after intubation, primary endpoint was defined as time of intubation. Patients treated with HCQ had severe disease at baseline. Overall, 346 patients (25.1%) had a primary endpoint event. In unadjusted analysis, patients in HCQ arm had more primary endpoint events. However, propensity matched analysis showed no significant difference.[@bib20]

Because these studies with CQ and HCQ have different therapeutic regimens, heterogenous study population, unequal arms to compare, ill-defined outcomes, and non-reproducible results, further randomized trials are needed before recommending the routine use of HCQ in mild COVID-19. Recently, a large multinational registry analysis failed to show benefits of HCQ in COVID-19, which was later retracted because of inconsistencies in data set, and the analysis that was conducted.[@bib21]

Boulware *et al.* published a randomized trial of HCQ on postexposure prophylaxis of COVID-19 in 821 asymptomatic participants. There was no significant difference in incidence of new COVID-like illness across both arms (11.8% versus 14.3%). Adverse events were more common in HCQ arm as compared with placebo (40.1% vs 16.8%). Although recommended by many government authorities worldwide, benefits of HCQ as prophylactic agent are not clear as of now.[@bib22]

Lopinavir/ritonavir {#sec4}
===================

Lopinavir is a serine protease inhibitor, and ritonavir increases its plasma half-life by inhibiting CYP450. Cao *et al.* conducted open label RCT using lopinavir/ritonavir (LPV/RTV) in patients with severe COVID-19 ([Table 3](#tbl3){ref-type="table"} ). Approximately, 31% patients of total 199 were on mechanical ventilation at baseline. The authors found no significant difference in viral loads over time or viral loads as per disease severity. Also, there was no significant difference in clinical outcomes and mortality in patients treated with LPV/RTV versus standard of care. Median time to clinical improvement was shorter by 1 day in LPV/RTV arm. Overall mortality was 22%. There was possible benefit of early intervention in a *post hoc* subgroup analysis. Patients who were treated within 12 days of symptom onset had a trend toward reduced mortality.[@bib23] Table 3Clinical Studies Other Than Hydroxychloroquine in Patients With COVID-19.Table 3AuthorsType of study (No. of patients)Treatment armsStudy population (Prior treatment)Virologic outcomesClinical outcomesMVSerious adverse eventsDeathCommentsCao B *et al.* Mar 2020, China[@bib23]Open label RCT (1:1) (n = 199)Lopinavir-ritonavir (400/100 mg 12hrly) x 14 d vs Standard of careSevere COVID-19: (O~2~ sat \<94%, PaO~2~: FiO~2~ \<300) (11% on INF treatment)No difference in viral loads over time or as per disease severityNo difference in clinical improvement (HR 1.31)30.7% on MV and 2% on ECMO20% (GI AEs more common, 13.8% discontinued)19.2% vs 25%No significant difference in RNA negativity, clinical outcome or mortalityGrein J *et al.* Apr 2020, (US, Europe, Japan)[@bib24]Compassionate use study (n = 53)Remdesivir 200 mg IV D1, 100 mg IV D2-10.\
No control armSevere COVID-19: (O~2~ sat \<94%, PaO~2~: FiO~2~ \<300) (Treatment naïve)NRClinical improvement in 68%, Extubation 57%, Discharge 47%57% on MV and 8% on ECMO23% (LFT abnormality 23%, 8% discontinued)13%No virologic data, no control arm, significant clinical improvementWang Y *et al.* Apr 2020, China[@bib25]RCT (2:1) (n = 237)Remdesivir 200 mg IV D1, 100 mg IV D2-10 vs Placebo controlled armSevere COVID-19: (O~2~ sat \<94%, PaO~2~: FiO~2~ \<300 and pneumonia) (LPV/RTV, INF, Steroids)No significant reductions in viral loadNo difference in time to clinical improvement (HR 1.23)16% on MV and 1% on ECMO18% (12% discontinued)14%No difference in viral or clinical outcomes including mortalityBeigel JH *et al.* May 2020, USA[@bib26]Double blind, RCT (1:1) (n = 1063)Remdesivir 200 mg IV D1, 100 mg IV D2-10 vs Placebo controlled armHospitalized patients with lower respiratory tract infectionNRShortened time to recovery (11 d vs 15 d)25.6%21.1%7.1% at D14Ill defined patient population, virologic outcomes not reported, modest benefit in patients who were not on mechanical ventilationGoldman JD *et al.* May 2020, USA[@bib27]Open-label, RCT (1:1) (n = 397)Remdesivir 200 mg IV D1, 100 mg IV D2-5 vs Remdesivir 200 mg IV D1, 100 mg IV D2-10Severe COVID-19: (O~2~ sat \<94%, and pneumonia); excluded patients on mechanical ventilationNRClinical improvement in 64% vs 54% at D14None21% vs 35%8% vs 11%Lack of placebo arm, virologic outcomes not reported, cannot be extrapolated to critically ill patientsCai Q *et al.* Mar 2020, China[@bib28]Prospective, open-label non-RCT (n = 80)Oral FPV (D1: 1600 mg 12hrly; D2-14: 600 mg 12hrly) plus IFN-α inhalation (n = 35) vs LPV/RTV (D1-14: 400 mg/100 mg 12hrly) plus IFN-α inhalation (n = 45)Excluded Severe COVID-19 (Treatment naïve)Shorter viral clearance time (4 d Vs 11 d)Significant improvement in chest imaging (91.43% vs 62.22%)None11.4%NoneExcluded severe disease, only radiological outcomes definedChen C *et al.* Mar 2020, China[@bib29]RCT (1:1) (n = 240)Favipiravir (D1: 1600 mg 12hrly; D2-10: 600 mg 12hrly) vs Umifenovir (Arbidol) (200 mg 8hrly) for 10 daysChinese definition of COVID-19 pneumonia (PCR + rate: approx. 42%, Severe disease only in 11%, treatment naïve)NRQuicker relief from fever and cough, no difference in clinical recovery, oxygen support or non-invasive ventilationNone32% vs 23%NRNo difference in ICU admission, oxygen support, respiratory failure or mortalityLuo P *et al.* Mar 2020, China[@bib31]Observational study (n = 15)Tocilizumab (80--600 mg/dose); 5 received \>/ = 2 doses\
No control arm87% serious disease, CRP \>5.0 mg/L; IL-6 \>7.0 pg/mLNRClinical stabilization 60%, clinical improvement 7%, disease aggravation 13%NRNR20%Small sized and ill-defined study population, no discrete clinical outcomesAlattar R *et al.* May 2020, Qatar[@bib32]Observational study (n = 25)Tocilizumab median total dose was 5.7 mg/kg (range 3.7--20 mg/kg)\
No control armSevere COVID-19: (RR \> 30/min, O~2~ sat \<93%, PaO~2~: FiO~2~ \<300 and pneumonia) With raised CRP (HCQ, AZT, LPV/RTV, INF, RBV)NRRapid decline in fever and CRP levels, radiological improvement in 68% at D14, weaning off from invasive ventilation at D14 \> 50%, Discharge 36%84%92% at least one AE12%IL-6 levels not measured, no fixed dosage of Tocilizumab, confounders like concomitant multiple interventionsShen C *et al.* Mar 2020, China[@bib34]Observational study (n = 5)Convalescent plasma transfusion (SARS-CoV-2--IgG binding titer \>1:1000 and neutralization titer \>1:40)Critically ill COVID-19 and ARDS (Antivirals and steroids)Viral clearance by D12Resolution of ARDS and weaning from ventilator 80%, Discharge 60%AllNRNoneIncrease in neutralizing antibody titers, improvement in clinical statusDuan K *et al.* Apr 2020, China[@bib35]Observational study (n = 10)Convalescent plasma transfusion (SARS-CoV-2--IgG neutralization titer \>1:640)Severe COVID-19 and pneumonia (Antivirals and steroids)Viral clearance in all (7/7)Improved oxygen status 30%, stable 70%, discharge 30%30%NoneNoneTrend toward clinical, radiological and biochemical improvement[^3]

Remdesivir {#sec5}
==========

Remdesivir is a nucleotide analog and RNA polymerase inhibitor with *in vitro* activity against Ebola, SARS, MERS, and SARS-CoV-2. Grein *et al.* prospectively studied the role of remdesivir in a multicenter compassionate use study in patients with severe COVID-19. Of 61 patients, 57% were on mechanical ventilation at baseline ([Table 3](#tbl3){ref-type="table"}). Thirty-six patients (68%) had an improvement in oxygen-support class over a median follow-up of 18 days. A total of 25 patients (47%) were discharged, and 7 patients (13%) died. Cumulative incidence of clinical improvement was higher in patients on non-invasive ventilation at baseline versus invasive ventilation. When stratified by age, clinical improvement was lower in patients with \>70 years of age compared with 50--70 years of age and highest in \<50 years of age.[@bib24]

In a double blind, placebo-controlled RCT, Wang *et al.* studied the role of remdesivir in 237 patients with severe COVID-19 pneumonia ([Table 3](#tbl3){ref-type="table"}). Concomitant use of lopinavir--ritonavir, interferons, and corticosteroids were allowed. Authors found no significant difference in time to viral clearance, time to clinical improvement, or mortality across both the groups. Patients who had symptom duration of 10 days or less had numerically faster time to clinical improvement. Overall mortality was 14%.[@bib25]

In a recent double-blind, placebo-controlled, multinational RCT, Beigel *et al.* studied role of remdesivir in 1063 hospitalized patients with COVID-19 and lower respiratory tract infections ([Table 3](#tbl3){ref-type="table"}). They found improved time to recovery (11 days vs 15 days) in remdesivir arm. In this study, 83.7% patients were on supplemental oxygen therapy including non-invasive and invasive mechanical ventilation. Mortality in remdesivir arm was 7.1%. Remdesivir improved outcomes mostly in patients requiring supplemental oxygen; there was no change in outcome in patients who were already on mechanical ventilation. This preliminary analysis included a heterogenous population of moderate to severe disease, and previous treatment status and virologic outcomes are not reported.[@bib26]

In another open-label, multinational RCT, Goldman *et al.* studied 5-day versus 10-day remdesivir in 397 patients with COVID-19 requiring supplemental oxygen ([Table 3](#tbl3){ref-type="table"}). Patients requiring mechanical ventilation were excluded at baseline. There was no significant difference in clinical recovery across both the arms. In multivariate analysis, age \< 65 years, baseline low oxygen requirement, and no biologic medication were associated with shorter time to clinical improvement.[@bib27]

These 4 clinical studies on remdesivir had heterogenous population at baseline with different disease severity, non-uniform reporting of virologic outcomes, and differently defined clinical outcomes. Large multicenter RCTs with well-defined population at baseline which show virologic, clinical, radiological, and mortality improvements are the need of hour. With the current evidence, remdesivir improves clinical outcomes when given early during moderate to severe disease.

Favipiravir {#sec6}
===========

Favipiravir is a purine nucleotide with *in vitro* activity against SARS-CoV-2. It is approved for the treatment of influenza in Japan. In an open label control study from China involving 80 patients without severe COVID-19, Cai *et al.* compared favipiravir with inhalational interferon-α (INF-α) against LPV/RTV with inhalational INF-α ([Table 3](#tbl3){ref-type="table"}). Authors found better therapeutic responses in favipiravir arm with early radiological resolution of pneumonia and shorter time to viral clearance. No clinical outcomes were reported in this study.[@bib28]

Umifenovir (Arbidol) acts by inhibiting the membrane fusion of viral envelope. It is approved for treatment of influenza in Russia and China. Chen *et al.* studied favipiravir versus arbidol in a prospective RCT comprising of 240 patients. Patients were included as per Chinese definition of COVID-19 pneumonia with only 42% nasopharyngeal swab positivity at inclusion. Severe disease was present only in 11% of total patients. Authors found quicker relief from fever and cough in favipiravir arm. There was no difference in need of auxiliary oxygen therapy or non-invasive mechanical ventilation. Virologic outcome was not assessed.[@bib29]

Tocilizumab {#sec7}
===========

Tocilizumab (TCZ) is a monoclonal antibody against interleukin-6 (IL-6) and has been used in patients with inflammatory disorders like Juvenile rheumatoid arthritis and Crohn\'s disease. TCZ inhibits IL-6 receptors (IL-6R) and reduces the inflammatory milieu including acute phase reactants like C-reactive protein (CRP). There is transient elevation in serum levels of IL-6 and soluble IL-6R (sIL-6R) after TCZ administration. It is suggested that TCZ forms immune complexes with sIL-6R, thereby increasing elimination half-life of sIL-6R. Free IL-6 levels are increased because IL-6R--mediated consumption of IL-6 is inhibited by the unavailability of TCZ-free IL-6R as long as TCZ is available in circulation. Increased level of free IL-6 during TCZ treatment closely reflects the actual endogenous IL-6 production and true disease activity. If the basic cause of IL-6 overproduction is addressed, IL-6 levels should subsequently decrease by natural degradation.[@bib30]

Luo *et al.* used TCZ in 15 patients (87% with severe disease) of COVID-19 who had raised CRP (\>5.0 mg/L) and IL-6 (\>7.0 pg/mL) at baseline. TCZ was given at (80--600 mg/dose); 5 patients received ≥2 doses of TCZ. Eight patients also received steroids. There was rapid decrease in CRP in all patients. Serum IL-6 level initially spiked and then decreased after TCZ therapy in 10 patients. A persistent and dramatic increase of IL-6 was observed in 4 patients who had treatment failure. Three patients died, 2 had disease aggravation, 1 had clinical improvement, and 9 had clinical stabilization after TCZ therapy. Virologic data were not assessed in the study.[@bib31]

Recently, Alattar *et al.* published their experience with TCZ in 25 patients with severe COVID-19 from Qatar. All patients had received at least 2 concomitant investigational antivirals before TCZ. IL-6 levels and viral loads were not measured. There was significant reduction in CRP levels after TCZ therapy; median CRP was 193 mg/L on Day 1, 7.9 mg/L on Day 3, and \<6 mg/L on Day 7. Radiological improvement was seen in 68% patients at Day 14. Proportion of patients who were on invasive ventilation at the time of TCZ initiation decreased from 84% to 60% on Day 7 and 28% on Day 14. Nine patients (36%) were discharged and three (12%) died.[@bib32]

Convalescent plasma transfusion {#sec8}
===============================

The US FDA has issued guidance for use of investigational COVID-19 convalescent plasma in patients with laboratory confirmed severe or immediately life-threatening COVID-19. They recommended neutralizing antibody titers of at least 1:160 against SARS-CoV-2.[@bib33] Shen *et al.* first reported their experience of convalescent plasma therapy in 5 critically ill patients COVID-19 and acute respiratory distress syndrome (ARDS) ([Table 3](#tbl3){ref-type="table"}). Convalescent plasma used had SARS-CoV-2 IgG binding titer \>1:1000 and a neutralization titer \>1:40. All patients had received antivirals and steroids until the SARS-CoV-2 viral loads became negative. Transfusion of convalescent plasma was shown to be associated with normalization of body temperature, increase in pO~2~/FiO~2~, and decrease in Sequential Organ Failure Assessment (SOFA) score. Viral clearance was seen in all 5 patients by Day 12. Resolution of ARDS with subsequent weaning was seen in 4 patients by Day 12. There was no mortality reported; 3 patients were discharged, and 2 remained stable at Day 37. There was improvement in neutralizing antibody titer from 40--60 to 80--320 by Day 7.[@bib34]

Subsequently, Duan *et al.* reported their experience of 10 patients with severe COVID-19 pneumonia treated with convalescent plasma. Convalescent plasma used had SARS-CoV-2 neutralizing antibody titer \>1:160. Plasma transfusion was well tolerated with maintenance of antibody titers and clearance of viremia by Day 7. There was no mortality, and trend toward clinical, radiological, and biochemical improvements.[@bib35]

There is no approved treatment of SARS-CoV-2 at present. With elucidation of viral genome, combination of newer drugs with proven activity at different stages (like polypeptide synthetase inhibitors, replicase inhibitors) of SARS-CoV-2 lifecycle and disease pathogenesis may pave the way for viral elimination. With the available evidence so far, HCQ may be used as prophylaxis in high-risk individuals with unproven benefits. No recommendation regarding use of HCQ in treating COVID-19 can be made at present. Because favipiravir and lopinavir-ritonavir did not provide significant benefits in viral clearance or clinical improvement in severe disease, further randomized trials are necessary before recommending these drugs in clinical practice. Remdesivir improves clinical outcomes when given early during moderate to severe disease and should be strongly considered. TCZ has been found useful in patients with cytokine storm and elevated IL-6 levels. Convalescent plasma transfusion can be used as rescue therapy in critically ill COVID-19 pneumonia as a part of clinical trials. A suggested algorithm would be to categorize patients into low-risk and high-risk group at presentation. Remdesivir ± TCZ should be used early in the disease course, before multiorgan dysfunction sets in. Convalescent plasma can be used as rescue therapy in patients with multiorgan dysfunction. Further multicenter randomized trials are necessary for proving the benefit of these available, re-purposed drugs until newer drugs are available.
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[^1]: Abbreviations: AZT, azithromycin; CQ, chloroquine; COVID-19, COrona VIrus Disease-2019; HCQ, hydroxychloroquine; ICU, intensive care unit; NR, not reported; RCT, randomized control trial.

[^2]: Modified from Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med 2020.[@bib10]

[^3]: Abbreviations: AE, adverse events; ARDS, acute respiratory distress syndrome; AZT, azithromycin; CQ, chloroquine; COVID-19, COrona VIrus Disease-2019; CRP, C-reactive protein; ECMO, extracorporeal membrane oxygenation; GI, gastro-intestinal; HCQ, hydroxychloroquine; HR, hazard ratio; IL-6, interleukin-6; INF, interferon; LFT, liver function test; LPV/RPV, lopinavir/ritonavir; MV, mechanical ventilation; NR, not reported; RBV, ribavirin; RCT, randomized control trial; RR, respiratory rate.
